These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 27145457)

  • 1. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
    Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
    Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yin Yang-1 suppresses pancreatic ductal adenocarcinoma cell proliferation and tumor growth by regulating SOX2OT-SOX2 axis.
    Zhang JJ; Zhu Y; Zhang XF; Liu DF; Wang Y; Yang C; Shi GD; Peng YP; Zhang K; Tian L; Miao Y; Jiang KR
    Cancer Lett; 2017 Nov; 408():144-154. PubMed ID: 28867247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport.
    Nagarajan A; Dogra SK; Sun L; Gandotra N; Ho T; Cai G; Cline G; Kumar P; Cowles RA; Wajapeyee N
    Mol Cell; 2017 Aug; 67(4):685-701.e6. PubMed ID: 28803777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.
    You N; Li J; Gong Z; Huang X; Wang W; Wang L; Wu K; Zheng L
    Mol Carcinog; 2017 Feb; 56(2):607-624. PubMed ID: 27350032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
    Zheng Q; Tang J; Aicher A; Bou Kheir T; Sabanovic B; Ananthanarayanan P; Reina C; Chen M; Gu JM; He B; Alcala S; Behrens D; Lawlo RT; Scarpa A; Hidalgo M; Sainz B; Sancho P; Heeschen C
    J Exp Clin Cancer Res; 2023 Nov; 42(1):323. PubMed ID: 38012687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
    Conradt L; Godl K; Schaab C; Tebbe A; Eser S; Diersch S; Michalski CW; Kleeff J; Schnieke A; Schmid RM; Saur D; Schneider G
    Neoplasia; 2011 Nov; 13(11):1026-34. PubMed ID: 22131878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma.
    Liu P; Yang H; Zhang J; Peng X; Lu Z; Tong W; Chen J
    Sci Rep; 2017 Jul; 7(1):5186. PubMed ID: 28701723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.
    Jiang Y; Feng E; Sun L; Jin W; You Y; Yao Y; Xu Y
    Biomed Pharmacother; 2017 Nov; 95():685-691. PubMed ID: 28886528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.
    Ni S; Wang H; Zhu X; Wan C; Xu J; Lu C; Xiao L; He J; Jiang C; Wang W; He Z
    Oncotarget; 2017 Jan; 8(5):8010-8021. PubMed ID: 28030829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.
    Wang X; Breuer J; Garbe S; Giordano F; Brossart P; Feldmann G; Bisht S
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
    Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
    Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.
    Mace TA; Shakya R; Elnaggar O; Wilson K; Komar HM; Yang J; Pitarresi JR; Young GS; Ostrowski MC; Ludwig T; Bekaii-Saab T; Bloomston M; Lesinski GB
    Oncotarget; 2015 Dec; 6(42):44509-22. PubMed ID: 26575024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers.
    Li B; Feng Y; Hou Q; Fu Y; Luo Y
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N
    Tian J; Zhu Y; Rao M; Cai Y; Lu Z; Zou D; Peng X; Ying P; Zhang M; Niu S; Li Y; Zhong R; Chang J; Miao X
    Gut; 2020 Dec; 69(12):2180-2192. PubMed ID: 32312789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target.
    Du X; He K; Huang Y; Xu Z; Kong M; Zhang J; Cao J; Teng L
    Int J Oncol; 2020 Mar; 56(3):761-771. PubMed ID: 32124956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.